What Legitimate Care Looks Like

The molecule isn’t what makes something legitimate. The medical infrastructure around it is.

A lot of people read our site and ask the same question: “Wait — if Eden and bmiMD also dispense compounded semaglutide, how is that different from what I can get from a peptide vendor?” The answer matters, because the difference is the entire reason one path lands you in the ER and the other doesn’t.

Same molecule. Two different worlds.

The gray market

You order from a website that sells “research peptides” with a disclaimer reading “not for human consumption.” That disclaimer isn’t a warning — it’s a legal shield. It means: nothing about this product is regulated.
No physician evaluates you. No bloodwork. No body-weight check. No screening for the conditions that make GLP-1s dangerous (gallbladder issues, gastroparesis, history of pancreatitis, MTC, MEN2).
The vial is filled by someone who is not a licensed pharmacist, in a facility that is not a licensed pharmacy, with raw API that may be from a non-GMP-compliant Chinese supplier. Janoshik tested vials sold as “99% pure” and found 7.7% actual semaglutide content. Endotoxin was present in every sample.
If something goes wrong, there is no malpractice insurance. No state medical board. No FDA recall mechanism. The vendor disappears overnight when they’re raided — the Vendor Graveyard documents at least five major exits in the past year.

LegitScript-certified compounded telehealth

You complete a medical intake reviewed by a US-licensed physician who is registered with your state medical board. They evaluate eligibility, order labs when needed, screen for contraindications, and write a prescription specific to you.
The prescription is filled by a 503A or 503B compounding pharmacy — a category of pharmacy explicitly authorized under federal pharmacy law (Drug Quality and Security Act, 2013). 503B outsourcing facilities register with the FDA and are inspected. 503A pharmacies are licensed by state boards of pharmacy.
The provider monitors your dose escalation, manages side effects, and adjusts treatment if needed. You have a real medical relationship — not just a checkout cart.
The company maintains LegitScript certification (independent regulatory monitoring) and HIPAA compliance. If something goes wrong, there is malpractice insurance, a state medical board complaint process, and a regulated pharmacy chain of custody.

THE THREE-LAYER TEST

Before you sign up with anyone, verify these three things independently.

This applies whether you’re considering a brand-only telehealth (Ro, Hims, LillyDirect) or a LegitScript-certified compounded telehealth (Eden, bmiMD, Enhance MD). Real providers pass all three tests. Gray-market vendors fail the first one.

1. Licensed provider, named

The site should name the supervising physician or medical director, including their state license number. You can verify any US physician at the state medical board where they’re licensed. If the site won’t name a real human doctor, it’s not a real medical provider.

2. Licensed pharmacy partner, named

For brand-only providers, the medication is dispensed from manufacturer-partnered pharmacies (NovoCare for Wegovy, LillyDirect for Zepbound). For LegitScript-certified compounded providers, the site should name the 503A/503B compounding pharmacy fulfilling prescriptions. Search NABP’s accredited list at nabp.pharmacy. The pharmacy should be searchable.

3. Independent certification, displayed

LegitScript displays its seal on certified merchant sites. You can verify any seal at legitscript.com’s public directory. NABP-accredited pharmacies operate on .pharmacy domains. If you see neither a LegitScript seal nor a verifiable pharmacy partnership — treat the site as a sales channel, not a medical service.

WHY A PARTNER MATTERS

Most of the harm we’ve documented didn’t come from a bad molecule. It came from no one watching.

Lottie Moss got a dose calibrated for someone twice her body weight. A real provider would have seen 110 pounds on the intake form and adjusted. The 200+ patients Dr. Watkins injected didn’t know they were getting research peptides — a real provider would have shown them the prescription. Amy Jenson’s appendix complication is a documented GLP-1 dysmotility risk that her provider would have flagged on follow-up.

The gray-market argument has always been: the doctor is just a gatekeeper. Save the consultation fee, get the same molecule, do it yourself.

The doctor is not the gatekeeper. The doctor is the person who notices when the dose is wrong for your body, when your gallbladder is acting up, when your TSH suggests an underlying issue, when your reaction at week three means you should drop down a tier. That’s the product you’re paying for. The molecule is the smaller half of it.